Join our daily newsletter At The Bell to receive exclusive market insights
- Invion (IVX) claims the first set of results from in-vitro lab tests of its INV043 product confirm the drug’s potential to treat the full range of anal cancers
- The tests, completed at the Peter MacCallum Cancer Centre in Melbourne, show the drug is effective against six squamous cell carcinoma cell lines that are linked to anal cancers
- The company has now commenced preclinical testing using topical delivery of INV043 before moving to clinical human testing
- Invion says these new findings are consistent with the results of work done using the drug on other cancer types at the Hudson Institute
- Shares in Invion are up 16.67 per cent and trading at 1.4 cents at 11:38 am AEST
Invion (IVX) has reported the first set of results from in-vitro lab tests of its INV043 product confirmed the drug’s potential to treat the full range of anal cancers
At the Peter MacCallum Cancer Centre in Melbourne, Invion tested the drug on squamous cell carcinoma (SCC) cell lines, which are linked to anal cancers. The company said the tests found INV043 to be effective against the six SCC cell lines that covered the full range of those types of cancers.
Further, Invion said the overall results were consistent with the outcomes achieved at the Hudson Institute back in May, which tested the drug with ICI therapy as a treatment for other cancers.
Professor Robert Ramsay, who conducted the study at Hudson, also led this study and said the investigation into INV043 as a treatment for anal cancer was Peter Mac’s “immediate focus”.
“SCC cell lines from the full range of anal cancers, from primary to metastatic and molecular subtypes, all respond to the killing action of INV032,” Professor Ramsay said.
“Preclinical testing using topical delivery of INV043 has now started as a prelude to moving to clinical testing in patients with anal SCC.”
According to Invion, anal cancers are particularly difficult to treat and most are SCCs that line the surface of the anal canal. The company said the global anal cancer market was forecast to hit $1.84 billion by 2028.
The company said it had added this study as another clinically important class of tumours to the spectrum of other tumours that were shown to be highly sensitive to INV043.
INV043 is Invion’s lead drug candidate, and the company said it represented the next generation of photodynamic therapy, which aims to treat multiple types of cancer.
Shares in Invion were up 16.67 per cent and trading at 1.4 cents at 11:38 am AEST.
